Home › Merck Statement regarding Role of PNEUMOVAX 23 (Pneumococcal Vaccine Polyvalent) in Updated ACIP Recommendations for Pneumococcal Vaccination in Adults
 

Keywords :   


Merck Statement regarding Role of PNEUMOVAX 23 (Pneumococcal Vaccine Polyvalent) in Updated ACIP Recommendations for Pneumococcal Vaccination in Adults

2014-08-13 23:58:00| Merck.com - Product News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today provided the following statement regarding the U.S. Centers for Disease Control and Preventions (CDCs) Advisory Committee on Immunization Practices (ACIPs) updated pneumococcal vaccine recommendations for adults 65 years of age and older. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Skip Irvine, 215-652-6059orInvestors:Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: in updated statement role

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
18.06Apple scraps its Pay Later loan scheme in US
18.06Potential Tropical Cyclone One Public Advisory Number 2
18.06Summary for Potential Tropical Cyclone One (AT1/AL012024)
18.06Potential Tropical Cyclone One Graphics
18.06Potential Tropical Cyclone One Wind Speed Probabilities Number 2
18.06Potential Tropical Cyclone One Forecast Advisory Number 2
18.06Potential Tropical Cyclone One Graphics
18.06Atlantic Tropical Weather Outlook
More »